Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2018

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2018-12-20: Form 6-K; Period of report 2018-12-20; Description BEVESPI AEROSPHERE APPROVED IN THE EU FOR COPD; Document a1580l.htm.
  • 2018-12-20: Form 6-K; Period of report 2018-12-20; Description LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL; Document a0476l.htm.
  • 2018-12-20: Form 6-K; Period of report 2018-12-20; Description PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS; Document a0881l.htm.
  • 2018-12-19: Form 6-K; Period of report 2018-12-19; Description FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPY; Document a0432l.htm.
FiledFormPeriod of reportDescriptionDocument
2018-12-206-K2018-12-20BEVESPI AEROSPHERE APPROVED IN THE EU FOR COPDa1580l.htm
2018-12-206-K2018-12-20LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIALa0476l.htm
2018-12-206-K2018-12-20PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALSa0881l.htm
2018-12-196-K2018-12-19FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPYa0432l.htm
2018-12-186-K2018-12-18ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISEa8041k.htm
2018-12-146-K2018-12-14DIRECTORATE CHANGEa4541k.htm
2018-12-076-K2018-12-07UPDATE ON THE PHASE III EAGLE TRIAL OF IMFINZIa7489j.htm
2018-12-066-K2018-12-06DIVESTMENT OF RIGHTS TO COVIS COMPLETEDa5795j.htm
2018-12-046-K2018-12-04DIRECTOR/PDMR SHAREHOLDINGa4230j.htm
2018-12-036-K2018-12-03BLOCK LISTING INTERIM REVIEWa2814j.htm
2018-12-036-K2018-12-03TOTAL VOTING RIGHTSa2802j.htm
2018-12-036-K2018-12-03GRUNENTHAL AGREEMENT FOR NEXIUM VIMOVO COMPLETEDa1366j.htm
2018-11-266-K2018-11-26US FDA GRANTS FASENRA ODD FOR EGPAa4118i.htm
2018-11-166-K2018-11-16ASTRAZENECA PROVIDES UPDATE ON PHASE III MYSTICa5539h.htm
2018-11-136-K2018-11-13ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBIa1599h.htm
2018-11-136-K2018-11-13US FDA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZAa9782g.htm
2018-11-136-K2018-11-13FARXIGA SIGNIFICANTLY REDUCED HOSPITALISATION FORa9744g.htm
2018-11-086-K2018-11-08AZN: YEAR-TO-DATE AND Q3 2018 RESULTSa7037g.htm
2018-11-066-K2018-11-06DIVESTMENT OF RIGHTS TO COVIS PHARMAa4535g.htm
2018-11-016-K2018-11-01TOTAL VOTING RIGHTSa0650g.htm
2018-10-316-K2018-10-31ADDITIONAL FINANCIAL INFORMATION-GRUNENTHAL DEALa8527f.htm
2018-10-306-K2018-10-30GRUNENTHAL AGREEMENT FOR RIGHTS TO NEXIUM VIMOVOa5971f.htm
2018-10-236-K2018-10-23ASTRAZENECA EXTENDS INNATE PHARMA COLLABORATIONa8275e.htm
2018-10-226-K2018-10-22LYNPARZA SHOWS 70% REDUCTION IN PFS OVARIAN CANCERa7229e.htm
2018-10-196-K2018-10-19CHMP POSITIVE OPINION BEVESPI AEROSPHEREa6420e.htm
2018-10-166-K2018-10-16FDA ORPHAN DRUG FOR LYNPARZA IN PANCREATIC CANCERa1192e.htm
2018-10-016-K2018-10-01TOTAL VOTING RIGHTSa5571c.htm
2018-10-016-K2018-10-01ATACAND AGREEMENT WITH CHEPLAPHARM COMPLETEDa4350c.htm
2018-09-286-K2018-09-28PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NEDa3969c.htm
2018-09-256-K2018-09-25OVERALL SURVIVAL DATA FOR IMFINZI: STAGE III NSCLCa8822b.htm
2018-09-246-K2018-09-24EMA APPROVES AZ'S IMFINZI FOR STAGE III NSCLCa7568b.htm
2018-09-246-K2018-09-24FARXIGA GETS POSITIVE RESULT IN DECLARE-TIMI 58a6661b.htm
2018-09-146-K2018-09-14FDA APPROVES AZS LUMOXITI IN HAIRY CELL LEUKAEMIAa7537a.htm
2018-09-076-K2018-09-07TEZEPELUMAB FDA BREAKTHROUGH THERAPY DESIGNATIONa0616a.htm
2018-09-066-K2018-09-06DIRECTORATE CHANGEa9174z.htm
2018-09-046-K2018-09-04TOTAL VOTING RIGHTSa6100z.htm
2018-08-316-K2018-08-31ASTRAZENECA UPDATE ON ANIFROLUMAB IN SLEa3329z.htm
2018-08-306-K2018-08-30EC APPROVES BYDUREON BCISE DEVICE FOR T2 DIABETESa2406z.htm
2018-08-236-K2018-08-23ASTRAZENECA PIIIB TRIAL UPDATE FOR BEVESPI IN COPDASTRAZENECA PIIIB TRIAL UPDATEa6232y.htm
2018-08-216-K2018-08-21AZ'S TAGRISSO APPROVED IN JAPAN FOR 1ST-LINE NSCLCa3993y.htm
2018-08-176-K2018-08-17FORM 6-Kdp94630_6k.htm
2018-08-156-K2018-08-15ASTRAZENECA PRICES A $3BN BOND ISSUEa8510x.htm
2018-08-106-K2018-08-106-Ka18-18404_16k.htm
2018-08-036-K2018-08-03EMA GRANTS OD FOR SELUMETINIB IN NF1a6775w.htm
2018-08-016-K2018-08-01TOTAL VOTING RIGHTSa5156w.htm
2018-07-276-K2018-07-27CHMP RECOMMENDS IMFINZI FOR STAGE III NSCLCa0432w.htm
2018-07-266-K2018-07-266-Ka18-14307_16k.htm
2018-07-246-K2018-07-24ATACAND TO BE DIVESTED TO CHEPLAPHARM IN EUROPEa5182v.htm
2018-07-186-K2018-07-18HOLDING(S) IN COMPANYa0319v.htm
2018-07-026-K2018-07-02TOTAL VOTING RIGHTSa2845t.htm
2018-07-026-K2018-07-02LYNPARZA APPROVED IN JAPAN FOR BRCAM BREAST CANCERa1288t.htm
2018-07-026-K2018-07-02IMFINZI APPROVED IN JAPAN FOR STAGE III NSCLCa1279t.htm
2018-06-296-K2018-06-29BYDUREON RECEIVES POSITIVE CHMP OPINION FOR BCISEa1058t.htm
2018-06-286-K2018-06-28AZ AND LUYE PHARMA COMPLETE AGREEMENT FOR SEROQUELa9351s.htm
2018-06-276-K2018-06-27LYNPARZA: SIGNIFICANT PFS 1ST-LINE OVARIAN CANCERa6864s.htm
2018-06-266-K2018-06-26BOARD COMMITTEE CHANGESa5291s.htm
2018-06-226-K2018-06-22PUBLICATION OF A PROSPECTUSa2103s.htm
2018-06-126-K2018-06-12UPDATE: LANABECESTAT PHASE III ALZHEIMER'S TRIALSa0765r.htm
2018-06-086-K2018-06-08EU APPROVES TAGRISSO FOR 1ST-LINE NSCLCa8518q.htm
2018-06-086-K2018-06-08DIRECTOR DECLARATIONa7114q.htm
2018-06-016-K2018-06-01BLOCK LISTING INTERIM REVIEWa0481q.htm
2018-06-016-K2018-06-01TOTAL VOTING RIGHTSa0466q.htm
2018-06-016-K2018-06-01DIRECTOR DECLARATIONa0234q.htm
2018-05-306-K2018-05-30UPDATE ON TERRANOVA PIII TRIAL FOR FASENRA IN COPDa6015p.htm
2018-05-256-K2018-05-25AZS IMFINZI: SIGNIFICANT OS IN STAGE III NSCLCa2686p.htm
2018-05-216-K2018-05-21AZ REGULATORY SUBMISSION IN JAPAN FOR FORXIGAa6564o.htm
2018-05-216-K2018-05-21US FDA APPROVES LOKELMA FOR ADULT HYPERKALAEMIAa6459o.htm
2018-05-186-K2018-05-18RESULT OF AGMa6381o.htm
2018-05-186-K2018-05-18AZN: Q1 2018 RESULTSa4988o.htm
2018-05-116-K2018-05-11ASTRAZENECA UPDATE ON FASENRA PIII TRIAL IN COPDa7359n.htm
2018-05-086-K2018-05-08EMA APPROVES LYNPARZA: MAINTENANCE OVARIAN CANCERa3572n.htm
2018-05-076-K2018-05-07AZ AND LUYE PHARMA ENTER AGREEMENT FOR SEROQUELazn201805076k.htm
2018-05-046-K2018-05-04DIRECTOR DECLARATIONa1832n.htm
2018-05-016-K2018-05-01TOTAL VOTING RIGHTSa7768m.htm
2018-04-276-K2018-04-27AZ: POSITIVE CHMP FOR TAGRISSO FIRST-LINE NSCLCa4183m.htm
2018-04-246-K2018-04-24ASTRAZENECA:HIGH LEVEL RESULTS OF THE ARCTIC TRIALa8555l.htm
2018-04-196-K2018-04-19FDA APPROVES TAGRISSO FOR 1ST-LINE USE IN NSCLCa3988l.htm
2018-04-136-K2018-04-13NOTICE OF AGMa8711k.htm
2018-04-136-K2018-04-136-Kd541056d6k.htm
2018-04-056-K2018-04-05DIRECTORATE CHANGEa8737j.htm
2018-04-036-K2018-04-03TOTAL VOTING RIGHTSa6650j.htm
2018-04-036-K2018-04-03FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIAa5384j.htm
2018-04-036-K2018-04-03AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EUa5381j.htm
2018-03-286-K2018-03-28DIRECTOR/PDMR SHAREHOLDINGa2695j.htm
2018-03-266-K2018-03-26DIRECTOR/PDMR SHAREHOLDINGa9429i.htm
2018-03-226-K2018-03-22LOKELMA APPROVED IN THE EUa6720i.htm
2018-03-126-K2018-03-12ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINEa3431h.htm
2018-03-076-K2018-03-07FILING OF FORM 20-F WITH SECa9077g.htm
2018-03-066-K2018-03-06ANNUAL FINANCIAL REPORTa8332g.htm
2018-03-016-K2018-03-01TOTAL VOTING RIGHTSa4369g.htm
2018-02-236-K2018-02-23LYNPARZA CHMP FOR OVARIAN CANCER MAINTAINANCEa8143f.htm
2018-02-206-K2018-02-20ASTRAZENECA'S IMFINZI APPROVED FOR STAGE III NSCLCa2063f.htm
2018-02-156-K2018-02-15SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUSa9703e.htm
2018-02-056-K2018-02-05DIRECTOR/PDMR SHAREHOLDINGa9443d.htm
2018-02-026-K2018-02-02AZN: FULL-YEAR 2017 RESULTSazn.htm
2018-02-016-K2018-02-01TOTAL VOTING RIGHTSa6636d.htm
2018-01-266-K/A2018-01-26AZ REPORTS PHASE III RESULTS FOR PT010 IN COPDa1207d6ka.htm
2018-01-266-K2018-01-26AZ REPORTS PHASE III RESULTS FOR PT010 IN COPDa9902c.htm
2018-01-196-K2018-01-19ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPANa3211c.htm
2018-01-196-K2018-01-19LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCERa3185c.htm
Advertisement